MedTrace Logo

Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma

NCT07600151 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2026-05-20

No results posted yet for this study

Summary

This study is researching an experimental five-drug combination called etentamig, isatuximab, bortezomib, lenalidomide, and dexamethasone. The study is focused on participants with newly diagnosed multiple myeloma (NDMM) and high-risk disease who are eligible for autologous stem cell transplantation.

Conditions

Interventions

DRUG

Etentamig

Administered per the protocol

DRUG

Isatuximab

Administered per the protocol

DRUG

Bortezomib + Lenalidomide + Dexamethasone

Administered per the protocol

Sponsors & Collaborators

  • AbbVie

    collaborator INDUSTRY

  • Sanofi

    collaborator INDUSTRY

  • Universitätsklinikum Hamburg-Eppendorf

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-12-01
Primary Completion
2036-09-30
Completion
2036-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07600151 on ClinicalTrials.gov